Intraperitoneal Immune Checkpoint Inhibitor for Malignant Ascites

Launched by CHINA MEDICAL UNIVERSITY HOSPITAL · Feb 16, 2023

Keywords

ClinConnect Summary

Malignant ascites appear when cancer cells metastasize to peritoneal cavity and interfere the circulation of lymph and blood. Patients with malignant ascites suffer from abdominal fullness, abdominal pain, poor intake, decreased nutrition, disability, and eventually inability to further anticancer treatment. Malignant ascites put a heavy burden on patient, their family, society and health care system.

Malignant ascites from cancers of stomach, pancreas and biliary tract are more refractory to intravenous chemotherapy or intraperitoneal chemotherapy than ascites from ovarian or chemo-naïve ...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients have cyto-/histologically confirmed malignant ascites from gastric, pancreatic or biliary tract adenocarcinoma
• • Patients have malignant ascites more than 1000ml
• • Patients have no history of prior intraperitoneal therapy for malignant ascites
• • Patients have life expectancy of at least 4 weeks
• • Patients have adequate platelet count ≥ 50,000/ul
• • Women or men of reproductive potential should agree to use an effective contraceptive method
• • All patients must be informed of the investigational nature of this study and must sign written informed consents.
• Exclusion Criteria:
• • Patients have ascites which is related to causes other than the malignancies
• • Patients who are receiving intraperitoneal treatment for their malignant ascites including therapeutic paracentesis
• • Patients with active infection
• • Patients with bleeding disorders
• • Patient with active cardiopulmonary disease or history of ischemic heart disease
• • Patients have intolerant abdominal pain
• • Patients who have serious concomitant systemic disorders incompatible with the study, i.e. poorly controlled diabetes mellitus, auto-immune disorders, cirrhosis of the liver, and the rest will be at the discretion of in-charged investigator